Navigation Links
Center Of Reproductive Medicine Participates In The Thrive-IVF Research Study To Help Improve Pregnancy Success Rates And Outcomes In Women With A History Of Repeated In Vitro Fertilization (IVF) Failures
Date:9/26/2013

WEBSTER, Texas, Sept. 26, 2013 /PRNewswire/ -- The Center of Reproductive Medicine today announced its participation in the Thrive-IVF Research Study, a Phase 2 clinical trial sponsored by Nora Therapeutics, Inc., to evaluate the efficacy, safety and tolerability of NT100 in women who have had repeated in vitro fertilization (IVF) failures despite having good quality embryos. A novel biologic agent similar to a naturally occurring protein in the female reproductive tract, NT100, is being specifically designed and developed for use following in vitro fertilization (IVF) procedures to improve pregnancy success rates and outcomes.

"We are delighted to be part of the Thrive-IVF Research Study to help evaluate a unique treatment option that could help improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful IVF procedures," said Vicki L. Schnell MD, FACOG, Thrive-IVF study investigator, and founder and medical director, Center of Reproductive Medicine.

More than seven million couples in the U.S. suffer from infertility and 10 percent of women of childbearing age in the developed world experience infertility in any given 12-month period. While significant research efforts in IVF have been focused on the embryo, it is estimated that three-fourths of all embryos that are transferred still fail to implant in the uterus. 

A critical part of the equation for the establishment and maintenance of a successful pregnancy is the presence not only of a good embryo, but also a favorable maternal environment for the embryo to implant and thrive. NT100's novel mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. There are currently no FDA-approved therapies focused on this critical dimension of endometrial receptivity.

"Nora believes that the Center of Reproductive Medicine is an ideal partner for this important infertility study," said Jeffrey K Tong, Ph.D., President and CEO, Nora Therapeutics. "We are excited to advance our NT100 clinical program with the goal of generating the evidence needed to earn FDA approval as the first and only treatment indicated to improve pregnancy success rates and outcomes for women with a history of repeated IVF failures."

About the Thrive-IVF Research Study
The Thrive-IVF Research Study (NT-03) is a randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy, safety and tolerability of NT100 in approximately 150 women 21-38 years of age who have had repeated (three or more) IVF failures despite having good-quality embryos. Study participants will be randomized to receive NT100 (low or high dose) or placebo. The study will be conducted at approximately 15-20 clinical sites in major metropolitan areas across the U.S. Visit http://www.thriveivf.com or www.clinicaltrials.gov for more information.

About Center of Reproductive Medicine
Established in 1993, Center of Reproductive Medicine (CORM) is a privately-owned company located in Webster and Beaumont, TX. Their state-of-the-art facility includes a surgery suite and IVF lab that allows treatment of all fertility related diagnoses. With three fertility specialists, they have more than twenty-five years combined experience and consistently rank high in fertility success rates in the area. Their donor egg program has been named number one in Texas for the past several years. 

About Nora Therapeutics, Inc.
Nora Therapeutics, Inc. is a specialty biopharmaceutical company focused on developing therapeutics to address unmet clinical needs in reproductive medicine. Nora's lead compound, NT100, is being specifically designed and developed for use following in vitro fertilization (IVF) procedures to improve pregnancy success rates and outcomes. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100's mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. For more information about Nora Therapeutics, visit www.noratherapeutics.com.


'/>"/>
SOURCE Nora Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. U.S. Blood Centers Pursue an Evolving Role in Cell Therapies
2. NASA Scientists and Silicon Valley Space Center Partners Make Home Team Bid for Moffett Federal Airfield Development
3. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
4. Blood Centers of America Experiences Record Growth
5. Elekta Opens Global Education Center for Oncology and Neuroscience Professionals
6. Miami’s Preferred Cord Blood Laboratory, GeneCell International, Partakes in North Shore Medical Center and Hialeah Hospital’s OB/GYN Symposium
7. Avon Foundation for Women, NIH, and the Center for Advancing Innovation Launch Start-Up Challenge to Advance Breast Cancer Biomedical Invention
8. TriCore Reference Laboratories Named First Next-Generation Sequencing Center of Excellence by Life Technologies
9. Animal Rehabilitation and Wellness Center Gives Castle Rock Golden Retriever a Second Chance to Enjoy Life with Stem Cell Therapy
10. West Nile Virus Reported from New York to Long Beach; The Center for the Biology of Chronic Disease (CBCD) Urges the Public to Take Precautions
11. Chinese Leader in Genomics Joins Science Center's Port Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):